These Analysts Revise Their Forecasts On Snowflake After Q2 Results

Snowflake Inc (NYSE: SNOW)) reported better-than-expected second-quarter earnings.

Snowflake Inc (NYSE:SNOW)) reported better-than-expected second-quarter earnings.

Snowflake said second-quarter revenue increased 36% year-over-year to $674.02 million, which beat the consensus estimate of $662.24 million. The company reported quarterly earnings of 25 cents per share, which beat analyst estimates of 10 cents per share.

Snowflake sees third-quarter product revenue of $670 million to $675 million versus $640.2 million in the second quarter. The company expects full-year product revenue to be between $2.6 billion.

Snowflake shares fell 5% to trade at $147.80 on Thursday.

These analysts made changes to their price targets on Snowflake following earnings announcement.

  • Piper Sandler cut the price target on Snowflake from $210 to $205. Piper Sandler analyst Brent Bracelin maintained an Overweight rating.
  • Barclays lowered the price target on Snowflake from $190 to $183. Barclays analyst Raimo Lenschow maintained an Overweight rating.
  • Raymond James slashed the price target on Snowflake from $180 to $170. Raymond James analyst Simon Leopold maintained an Outperform rating.
  • Wells Fargo increased the price target on Snowflake from $195 to $200. Wells Fargo analyst Michael Turrin maintained an Overweight rating.

Read This Next: Investor Optimism Improves Further After Nasdaq Gains For Three Straight sessions

Total
0
Shares
Related Posts
Read More

AstraZeneca Announced Ultomiris Approved in Japan for gMG

Ultomiris (ravulizumab) has been approved in Japan for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive and whose symptoms are difficult to control with high-dose intravenous immunoglobulin therapy (IVIg) or plasmaphaeresis.

AZN